|
인쇄하기
취소
|
KFDA approves new type 2 diabetic agent
Published: 2011-01-28 06:59:00
Updated: 2011-01-28 06:59:00
The Korea Food and Drug Administration said Monday it has approved Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor.
Developed by Bristol-Myers Squibb Company and AstraZeneca, Onglyza is indicated as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults for the treatment of type 2 diabetes mellitus.
Onglyza once daily can be used in combinat...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.